FDA Approves AstraZeneca's Etcamah in First ctDNA-Triggered Breast Cancer Treatment Switch
- Camizestrant, sold as Etcamah, is AstraZeneca's oral SERD, approved in combination with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer.
- The FDA's accelerated approval applies only when a blood-based ctDNA test detects an emerging ESR1 resistance mutation during ongoing first-line aromatase-inhibitor-plus-CDK4/6-inhibitor therapy, before any scan-confirmed disease progression.
- This is the first FDA approval in which a ctDNA liquid-biopsy signal alone, rather than radiographic progression, triggers a switch to a new regimen.
- FDA simultaneously approved a companion diagnostic, the Guardant360 CDx ctDNA assay, to identify the ESR1 mutation guiding this switch.
- Trial data cited showed the camizestrant combination improved progression-free survival versus continuing the prior regimen after the mutation appeared, though accelerated approval remains subject to confirmatory trial verification.
AstraZeneca just banked a regulatory first that's harder to copy than a molecule: switching therapy off a blood test before scans show progression. That head start matters in HR+/HER2- breast cancer, the biggest and most crowded segment in oncology, because rivals chasing ESR1-resistance plays now need their own drug plus their own FDA-blessed ctDNA pathway — a two-part bar, not one. Pairing with Guardant360 CDx also means AstraZeneca doesn't own the whole value chain; commercial success now hinges on oncologists actually ordering serial ctDNA testing during first-line therapy — a workflow change, not just a prescribing choice. If adoption sticks, AZ has a template — earlier, biomarker-triggered switching — to extend toward other resistance mutations and assets, turning a single approval into a broader precision-oncology moat rather than a one-off label.
FDA approves AstraZeneca's Etcamah, opening ctDNA-guided treatment paradigm in breast cancer ↗